| Co-Investigator(Kenkyū-buntansha) |
松平 浩 東京大学, 医学部附属病院, その他 (10302697)
澤田 良子 東京大学, 医学部附属病院, 病院診療医 (30648308)
岩瀬 哲 埼玉医科大学, 医学部附属病院, 教授 (60372372)
芳賀 信彦 東京大学, 医学部附属病院, 教授 (80251263)
|
|---|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Questionnaires (EQ-5D, NRS(Numerical Rating Scale) for pain, EORTC QLQ-PAL15 and BM22, generic screening tool, K6) were self-completed by 64 patients with bone metastasis recruited from April 2015 to June 2016 in our hospital. Of the 64 patients, 31 were male and 33 were female. Average age was 63.7. The average EQ-5D score was 0.58+-0.24. NRS, Physical Functioning (PAL15), Functional Interference (BM22), Emotional Functioning (PAL15), generic screening tool, K6, and PS (Performance Status) were co-related to EQ-5D by p<0.001. Psychosocial Aspects (BM22), SRE, previous chemotherapy, serum Ca corrected by Alb, and CRP were co-related to EQ-5D by p<0.05.
In conclusion, pain, physical function, and psychological factors seem to have strong effects on QOL of patients with bone metastasis. Consultation to physiatrists, orthopaedic surgeons, and clinical pshychotherapist might be important for improving the QOL of these patients.
|
